Last reviewed · How we verify
NCT04811365
(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation
trial testing Screening in Systemic Mast Cell Activation in 379 participants. Completed in 31 March 2023.
31 March 2023
Quick facts
| Lead sponsor | Blueprint Medicines Corporation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 379 |
| Start date | 29 June 2021 |
| Primary completion | 31 March 2023 |
| Estimated completion | 31 March 2023 |
| Sites | 23 locations across France, Italy, Belgium, United Kingdom, Germany, Switzerland, United States, Spain |
Drugs / interventions tested
- Screening
Conditions studied
- Systemic Mast Cell Activation — all drugs for Systemic Mast Cell Activation →
- KIT D816V Mutation — all drugs for KIT D816V Mutation →
Sponsor
Blueprint Medicines Corporation — full company profile →
Who can join
18 and older, any sex, with Systemic Mast Cell Activation or KIT D816V Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multi-center screening study with the primary objective to determine the prevalence of KIT D816V mutation in peripheral blood in patients with evidence of systemic mast cell activation (MCA).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation.
Hartmann K, Alvarez-Twose I, Bernstein JA, Akin C, et al · · 2026 · PMID 41399928 · DOI 10.1016/j.jaci.2025.10.010
Verify or expand the search:
- PubMed search for NCT04811365
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Screening
Trials testing the same drug.
- NCT07143669 — Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations · recruiting
- NCT07225374 — Cisplatin-Based Chemotherapy Followed by Maintenance Avelumab in UTUC · Phase 2 · recruiting
- NCT07235332 — Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel. · enrolling by invitation
- NCT06887569 — Using Financial Incentives and Screening to Increase Engagement With Mental Health Services Among College Students in Ch · NA · completed
- NCT06439901 — Optimizing Bronchopulmonary Cancer Screening · NA · recruiting
Other Blueprint Medicines Corporation trials
Trials by the same sponsor.
- NCT07388511 — A Study of Elenestinib in Healthy Adult Female Participants · Phase 1 · recruiting
- NCT07264959 — An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) · not yet recruiting
- NCT07255638 — A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany · recruiting
- NCT07143669 — Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations · recruiting
- NCT06931405 — Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04811365 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Blueprint Medicines Corporation
- Last refreshed: 6 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04811365.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing